Genomics

Dataset Information

42

Cardiac gene expression profiling of heart failure treatment with the anti-ischemic drug ranolazine


ABSTRACT: Heart failure is a leading cause of cardiovascular mortality with limited options for treatment. We analyzed whether the anti-ischemic drug ranolazine could retard the progression of heart failure in an experimental model of heart failure induced by 6 months of chronic pressure overload. The study showed that 2 months of ranolazine treatment improved cardiac function of aortic constricted C57BL/6J (B6) mice with symptoms of heart failure as assessed by echocardiography. The microarray gene expression study of heart tissue from failing hearts relative to ranolazine-treated and healthy control hearts identified heart failure-specific genes that were normalized during treatment with the anti-ischemic drug ranolazine. Overall design: Microarray gene expression profiling was performed with heart tissue isolated from three study groups: (i) untreated 10 month-old C57BL/6J (B6) mice with heart failure induced by 6 months of abdominal aortic constriction (AAC), (ii) 10 month-old B6 mice with 6 months of AAC and two months of treatment with the anti-ischemic drug ranolazine (200 mg/kg), and (iii) age-matched, untreated, sham-operated B6 control mice.

INSTRUMENT(S): [Mouse430_2] Affymetrix Mouse Genome 430 2.0 Array

ORGANISM(S): Mus musculus  

SUBMITTER: Ursula Quitterer  

PROVIDER: GSE25766 | GEO | 2010-12-03

SECONDARY ACCESSION(S): PRJNA134067

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
GSE25766_RAW.tar Raw
filelist.txt Txt
Items per page:
1 - 2 of 2

Similar Datasets

2010-12-03 | E-GEOD-25766 | ArrayExpress
2010-12-03 | E-GEOD-25767 | ArrayExpress
2010-12-03 | GSE25767 | GEO
2010-12-03 | GSE25765 | GEO
2010-12-03 | E-GEOD-25765 | ArrayExpress
| PRJNA134067 | ENA
2013-01-01 | S-EPMC3896218 | BioStudies
2019-01-01 | S-EPMC6515545 | BioStudies
| PRJNA134069 | ENA
1000-01-01 | S-EPMC4077852 | BioStudies